ProfileGDS5678 / 1456596_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 68% 64% 65% 61% 60% 65% 62% 84% 86% 83% 79% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9765166
GSM967853U87-EV human glioblastoma xenograft - Control 23.9847466
GSM967854U87-EV human glioblastoma xenograft - Control 34.1848568
GSM967855U87-EV human glioblastoma xenograft - Control 43.8179464
GSM967856U87-EV human glioblastoma xenograft - Control 53.9143765
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7057361
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6951760
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.921965
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6883662
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3209384
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4813786
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1711683
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4412979
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2668485